TNFRSF8 and anaplastic large cell lymphoma: In addition to ALK fusion proteins and their associated signaling pathways, activation of ALK and its downstream effectors in ALK+ ALCL results in the expression of CD30, PD-L1, and B7-H3, which are potential drug targets in patients who are highly resistant to ALK TKIs.